Drugs / funobactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04802863 | Mar → May 2021 | bacterial infectious disease | Evopoint Biosciences Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-18 | Evopoint Biosciences Inc. | Regulatory 信诺维新药福诺巴坦（XNW4107）提交Pre-NDA申请，为HABP/VABP患者带来新希望 evopointbio.com ↗
苏州信诺维医药科技股份有限公司（简称“信诺维”或“公司”）今日宣布，其在研1类新药——福诺巴坦/亚胺培南/西司他丁，已于近日向国家药品监督管理局药品审评中心（CDE）提交了Pre-NDA申请，其有望成为全球首款广谱且对三大碳青霉烯耐药革兰阴性杆菌（CRO）具有强大抗菌活性的新型β-内酰胺类/β-内酰胺酶抑制剂（BL/BLI）药品。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-12-18 | Evopoint Biosciences Inc. | 信诺维新药福诺巴坦（XNW4107）提交Pre-NDA申请，为HABP/VABP患者带来新希望 evopointbio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | funobactam | “Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases.” PMID 42294651 ↗ Jun 2026 |
| Known as | XNW4107 | “Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases.” PMID 42294651 ↗ Jun 2026 |
| Action | Inhibit | “Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases.” PMID 42294651 ↗ Jun 2026 |
| Modality | Small molecule | — CHEMBL5095101 ↗ |
| Route | Intravenous | “Twenty participants received a 60 min intravenous infusion of imipenem 500 mg/cilastatin 500 mg combined with funobactam 250 mg every 6 h for five doses.” PMID 42294651 ↗ Jun 2026 |